FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308379112> ?p ?o ?g. }

• W4308379112 abstract "<h3>Background</h3> Immune checkpoint inhibitors (ICIs) are a first line and adjuvant treatment in advanced stage lung cancer. One of the main complications of ICI treatment is pneumonitis with an overall incidence of 2-5%; however, patient specific risk factors for developing ICI-pneumonitis (ICI-p) haven’t been well elucidated. ^1,2 We evaluated potential pre-treatment risk factors for ICI-p including pre-treatment interstitial abnormalities on computed tomography of the chest (CT chest). <h3>Methods</h3> We conducted a retrospective cohort study of consecutive patients with lung cancer who received at least one dose of ICI between 2015-2020 at The Ohio State University. Potential risk factors for ICI-p were recorded and summarized between those with and without pneumonitis. Among patients who developed pneumonitis, these factors were compared between Grade <3 and Grade >=3 severities as well as among patients with different cancer stage (3 vs 4). Multivariable survival analysis was used to examine the association of potential risk factors with pneumonitis. Pneumonitis cases were documented by the treating oncologist and retrospectively evaluated by an oncologist and pulmonologist. <h3>Results</h3> 473 patients with lung cancer were included, 401 with Non-Small Cell Lung Cancer and 72 with Small Cell Lung Cancer. 38 developed ICI-p and 435 did not. Of the potential risk factors, the following were significantly associated with ICI-p: pre-existing interstitial abnormalities (30.8% vs 4.2%, p < 0.001), prior concurrent chemoradiation (17.7% vs 4.2%, p <0.001), stage of cancer (19.8% for stage III vs 4.4% for stage IV, p < 0.001),), and type of immunotherapy (12.5% for PD1 vs 3.6% for chemo-IO, p < 0.001) (table 1). Pre-existing interstitial abnormalities remained strongly correlated with development of pneumonitis on multivariable analysis including prior chemoradiation, pre-treatment interstitial abnormalities, and type of immunotherapy, (hazard ratio 8.54 [4.45-16.42], p<0.001) (table 2). Interstitial abnormalities also remained significant in subgroup analysis of both stage 3 and 4 lung cancer (p<0.001). Patients with grade 3/4 pneumonitis had decreased overall survival compared to those with grade 1/2 pneumonitis (p = 0.0342) (figure 1). <h3>Conclusions</h3> Pre-existing interstitial abnormalities on CT chest is strongly associated with development of ICI-p in patients with lung cancer. It remains an independent risk factor after accounting for common treatment-related risk factors such as prior chemoradiation and chest radiation. Pre-treatment interstitial abnormalities could be utilized as a risk stratification tool to identify patients at highest risk for developing ICI-p, a devastating complication associated with higher mortality in more severe cases. <h3>Acknowledgements</h3> This study was supported by the National Institutes of Health (P30CA016058 and K12 CA133250). Research support provided by the REDCap project and The Ohio State University Center for Clinical and Translational Science grant support (National Center for Advancing Translational Sciences, Grant UL1TR002733) <h3>References</h3> Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis. <i>JAMA Oncology</i>.<b>2</b>(12):1607–1616. Wu J, Hong D, Zhang X, Lu X, Miao J. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. <i>Scientific Reports.</i><b>7</b>(1). <h3>Ethics Approval</h3> Human data was utilized in this project; CIRB approval was obtained and all participants provided informed consent prior to taking part in the study (Study number 2021C0069)." @default.
• W4308379112 created "2022-11-11" @default.
• W4308379112 creator A5003137655 @default.
• W4308379112 creator A5004712121 @default.
• W4308379112 creator A5006468163 @default.
• W4308379112 creator A5008598632 @default.
• W4308379112 creator A5014357050 @default.
• W4308379112 creator A5021542973 @default.
• W4308379112 creator A5035319531 @default.
• W4308379112 creator A5035430475 @default.
• W4308379112 creator A5044877762 @default.
• W4308379112 creator A5045110376 @default.
• W4308379112 creator A5081714993 @default.
• W4308379112 creator A5082350541 @default.
• W4308379112 creator A5084710012 @default.
• W4308379112 creator A5090780152 @default.
• W4308379112 creator A5091280788 @default.
• W4308379112 date "2022-11-01" @default.
• W4308379112 modified "2023-10-03" @default.
• W4308379112 title "442 Pre-treatment interstitial abnormalities is a risk factor for immune checkpoint inhibitor pneumonitis in patients with lung cancer" @default.
• W4308379112 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0442" @default.
• W4308379112 hasPublicationYear "2022" @default.
• W4308379112 type Work @default.
• W4308379112 citedByCount "0" @default.
• W4308379112 crossrefType "proceedings-article" @default.
• W4308379112 hasAuthorship W4308379112A5003137655 @default.
• W4308379112 hasAuthorship W4308379112A5004712121 @default.
• W4308379112 hasAuthorship W4308379112A5006468163 @default.
• W4308379112 hasAuthorship W4308379112A5008598632 @default.
• W4308379112 hasAuthorship W4308379112A5014357050 @default.
• W4308379112 hasAuthorship W4308379112A5021542973 @default.
• W4308379112 hasAuthorship W4308379112A5035319531 @default.
• W4308379112 hasAuthorship W4308379112A5035430475 @default.
• W4308379112 hasAuthorship W4308379112A5044877762 @default.
• W4308379112 hasAuthorship W4308379112A5045110376 @default.
• W4308379112 hasAuthorship W4308379112A5081714993 @default.
• W4308379112 hasAuthorship W4308379112A5082350541 @default.
• W4308379112 hasAuthorship W4308379112A5084710012 @default.
• W4308379112 hasAuthorship W4308379112A5090780152 @default.
• W4308379112 hasAuthorship W4308379112A5091280788 @default.
• W4308379112 hasBestOaLocation W43083791121 @default.
• W4308379112 hasConcept C121608353 @default.
• W4308379112 hasConcept C126322002 @default.
• W4308379112 hasConcept C143998085 @default.
• W4308379112 hasConcept C167135981 @default.
• W4308379112 hasConcept C2776256026 @default.
• W4308379112 hasConcept C2777714996 @default.
• W4308379112 hasConcept C2779524853 @default.
• W4308379112 hasConcept C50440223 @default.
• W4308379112 hasConcept C71924100 @default.
• W4308379112 hasConcept C90924648 @default.
• W4308379112 hasConceptScore W4308379112C121608353 @default.
• W4308379112 hasConceptScore W4308379112C126322002 @default.
• W4308379112 hasConceptScore W4308379112C143998085 @default.
• W4308379112 hasConceptScore W4308379112C167135981 @default.
• W4308379112 hasConceptScore W4308379112C2776256026 @default.
• W4308379112 hasConceptScore W4308379112C2777714996 @default.
• W4308379112 hasConceptScore W4308379112C2779524853 @default.
• W4308379112 hasConceptScore W4308379112C50440223 @default.
• W4308379112 hasConceptScore W4308379112C71924100 @default.
• W4308379112 hasConceptScore W4308379112C90924648 @default.
• W4308379112 hasLocation W43083791121 @default.
• W4308379112 hasOpenAccess W4308379112 @default.
• W4308379112 hasPrimaryLocation W43083791121 @default.
• W4308379112 hasRelatedWork W1967103478 @default.
• W4308379112 hasRelatedWork W2020488282 @default.
• W4308379112 hasRelatedWork W2032912323 @default.
• W4308379112 hasRelatedWork W2087332109 @default.
• W4308379112 hasRelatedWork W2133419159 @default.
• W4308379112 hasRelatedWork W2372561159 @default.
• W4308379112 hasRelatedWork W2375344515 @default.
• W4308379112 hasRelatedWork W2380382254 @default.
• W4308379112 hasRelatedWork W2390152934 @default.
• W4308379112 hasRelatedWork W4367672288 @default.
• W4308379112 isParatext "false" @default.
• W4308379112 isRetracted "false" @default.
• W4308379112 workType "article" @default.